View Older Stories
-
Kenvue (KVUE) call put ratio 2.9 calls to 1 put into quarter results
-
Kenvue (KVUE) call put ratio 8.1 calls to 1 put into quarter results
-
Jefferies Downgrades Kenvue Inc (KVUE) to Hold
-
Kimberly-Clark and Kenvue shareholders approve acquisition deal
-
RBC Capital on Kenvue Inc (KVUE): 'Expecting a Pressured Quarter'
-
RBC Capital Highlights Top Ideas and Focus Picks Across HPC, Beverages, and Packaged Food
-
Judge denies Texas AG's TRO against Kenvue over Tylenol marketing
-
Kenvue Inc (KVUE) PT Lowered to $21 at RBC Capital
-
Kenvue (KVUE) call put ratio 3.3 calls to 1 put after Kimberly-Clark (KMB) announced acquiring in cash, stock
-
Toms Capital Plans to hold on to Kenvue Shares - WSJ
-
Activist Investor D.E. Shaw Expected to Break Even on Kenvue After Kimberly-Clark Deal - WSJ
-
Kenvue jumps 22% on $48.7 billion Kimberly-Clark merger deal
-
Kenvue Inc. (KVUE) Tops Q3 EPS by 2c
-
Kimberly-Clark (KMB) call put ratio 1.9 calls to 1 put into acquiring Kenvue (KVUE)
-
Kenvue (KVUE) November 7 weekly calls active into Kimberly-Clark (KMB) to acquire
-
Stocks expected to have increasing option volume: KVUE JNJ KMB CDE NGD
-
Kenvue Inc. (KVUE) Tops Q3 EPS by 2c
-
HHS Secretary Kennedy on Tylenol: not enough evidence to show Tylenol definitively causes autism but some studies seem 'very suggestive'
-
Canaccord Genuity Downgrades Kenvue Inc (KVUE) to Hold
-
Kenvue (KVUE) to Name New Marketing Chief Following PR Crisis for Tylenol - WSJ
-
Evercore ISI Warns on Kenvue Inc (KVUE) Amid 3.5pct Decline: 'It's not just Tylenol'
-
Texas attorney general sues Johnson & Johnson and Kenvue over Tylenol marketing
-
Kenvue Inc (KVUE) PT Lowered to $23 at Jefferies
-
Starboard's Smith: Search Is Underway For New Kenvue (KVUE) CEO - Bloomberg
-
UBS Reiterates Neutral Rating on Kenvue Inc (KVUE) as Shares Down on Report of UK Class Action Suit
-
Canaccord Genuity Reiterates Buy Rating on Kenvue Inc (KVUE)
-
Kenvue (KVUE) Weakness Tied to Concerns About Baby Powder Suit in UK
-
Kenvue partners with Albert Invent to integrate AI into R&D processes
-
Trump: pregnant women, don't use Tylenol unless absolutely necessary
-
Kenvue (KVUE) on watch following Trump post
-
Rothschild upgrades Kenvue after Tylenol scare wipes $10 billion in market value
-
Rothschild Redburn Upgrades Kenvue Inc (KVUE) to Buy
-
Increasing unusual put option volume: K EWC UAMY SNDK UTHR BITF XP PL RITM BN KVUE
-
Kenvue shares rise despite Trump linking painkiller to autism risk
-
Kenvue (KVUE) call put ratio 1 call to 1.1 puts with a focus on November calls and puts amid headlines
-
Barclays Reiterates Equalweight Rating on Kenvue Inc (KVUE)
-
Kenvue Inc (KVUE) PT Lowered to $18 at Evercore ISI
-
US Advises Pregnant Women To Avoid Tylenol Over Fears Of Autism
-
Kenvue stock falls after report of Trump admin linking Tylenol to autism
-
Should you buy a dip in Kenvue stock? Jefferies weighs in
-
Goldman Sachs on Kenvue Inc (KVUE): 'We believe this news flow could pose reputational risk'
-
JPMorgan Defending Kenvue Inc (KVUE): 'Tylenol products already direct patients who are pregnant or breastfeeding to consult their healthcare provider before use'
-
Canaccord Genuity Defending on Kenvue Inc (KVUE), PT $26, 'Actual risk to KVUE should be minimal'
-
Kenvue Inc (KVUE) PT Lowered to $20 at Deutsche Bank
-
Kenvue Inc (KVUE) PT Lowered to $23 at Evercore ISI, 'Is the sell-off overdone?'
-
UBS Negative on Kenvue Inc (KVUE)
-
Kenvue (KVUE) call put ratio 1.6 calls to 1 put amid wide price movement
-
Evercore ISI: 'Tylenol constitutes a key profit center and sits at the core of Kenvue’s strategic value'
-
BofA Securities Defending Kenvue Inc (KVUE): 'We estimate Tylenol represents ~9% of KVUE’s sales', Sees 'widening discount as a particularly attractive entry point'
-
HHS spokesperson to CNBC on forthcoming autism report - until we release final report, claims about its contents are nothing more than speculation

